Research Compound Library

Mechanism, dosing, and data for every Aion compound.

One overview per research peptide. Where the molecule came from, what the published data actually shows, and how the standard research cycle is built. Educational frame only. For research use only.

10 compound research overviews

Pick a compound. Get mechanism, cycle, and data in one page.

Each page covers the published research, vial sizes, standard cycle window, side effect categories, and how the compound fits the broader research stack.

Soft tissueBPC-157
Why BPC-157 Got Banned in Sports (And Why It Matters)
Banned across every WADA-affiliated drug-tested sport. The S0 category, the science athletes were chasing, and the standard research cycle.
Read · 7 minUpdated · May 2026
Soft tissueTB-500
What TB-500 Does That BPC-157 Cannot
TB-500 binds G-actin. BPC-157 does not. One mechanism explains why the two get stacked instead of swapped.
Read · 7 minUpdated · May 2026
Skin and tissueGHK-Cu
What GHK-Cu Actually Does in Skin and Tissue
A copper tripeptide that sits between research peptide and dermatology compound. What the data shows on skin, scar, and hair work.
Read · 7 minUpdated · May 2026
LongevityNAD+
What NAD+ Actually Does (And Why Pills Don't Work)
Why oral NAD+ never reaches the cell, why subq beats IV for most research protocols, and what the longevity literature actually shows.
Read · 7 minUpdated · May 2026
GH axisCJC-1295 + Ipa
CJC-1295 + Ipamorelin: The Sleep Stack Explained
Why the two get paired, how the GH pulse hits during slow-wave sleep, and what changes in subjective recovery within the first two weeks.
Read · 7 minUpdated · May 2026
Visceral fatTesamorelin
Why Tesamorelin Targets Visceral Fat Specifically
A GHRH analog with FDA-approved data on visceral adipose reduction. Where it sits in the metabolic peptide stack and the standard cycle.
Read · 7 minUpdated · May 2026
Sexual researchPT-141
Why PT-141 Works Differently Than Every Other Sex Peptide
A melanocortin agonist that acts on the central nervous system, not the vascular pathway. Why the mechanism matters and the standard research protocol.
Read · 7 minUpdated · May 2026
Weight researchSemaglutide
Semaglutide: 15% Weight Loss in 68 Weeks of Data
The STEP trial data behind the FDA-approved version, how the research peptide compares, and the dose ladder used in most research cycles.
Read · 7 minUpdated · May 2026
Weight researchTirzepatide
Tirzepatide: 21% Weight Loss in 72 Weeks of Data
Dual GIP and GLP-1 agonist. The SURMOUNT trial numbers, why the dual mechanism beats single-agonist research, and the standard titration ladder.
Read · 8 minUpdated · May 2026
Weight researchRetatrutide
Retatrutide: 24% Weight Loss in 48 Weeks (Phase 2)
Triple agonist (GIP, GLP-1, glucagon). The Phase 2 data that put it ahead of tirzepatide on raw weight numbers and what researchers are watching for in Phase 3.
Read · 8 minUpdated · May 2026